Novartis Big Earners Beat Q1 Forecasts
But Disappointing Quarter For Beovu
Cosentyx defied the odds again by growing strongly despite US formulary changes, COVID-19 and fierce competition, while the jump in Entresto sales helped soften the drug's failure in a closely watched myocardial infarction study.
